Loading
A phase 3 trial of Nadofaragene firadenovec, Gemcitabine, Docetaxel and Pembrolizumab in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting.
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06545955 by Ferring Pharmaceuticals, with 250 participants planned, started 2024-10-01 and due to reach its primary completion in 2028-06-30. Interventions recorded: Nadofaragene Firadenovec, Gemcitabine, Docetaxel and Pembrolizumab.
Shares Ferring Pharmaceuticals, Nadofaragene firadenovec, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Ferring Pharmaceuticals, Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.